Study Identifies Gaps in End-of-Life Care for Patients Eligible for Both Medicaid and Medicare
November 10th 2021“Health care providers should be aware of this gap in care for dual-eligible patients and other vulnerable populations so that needs can be identified and resources can be appropriately directed.”
Pembrolizumab May Be Associated with Sustainable Relapse-Free Survival in High-Risk Melanoma
November 8th 2021After 6 months of additional follow-up, patients with resected high-risk stage II melanoma continued to experience improved relapse-free survival following treatment with adjuvant pembrolizumab.
Audiological Monitoring May Be Necessary in Very Young Children Receiving Cisplatin Treatment
November 5th 2021Cisplatin-induced hearing loss was found to be more prevalent in very young children receiving treatment; therefore, findings suggest that audiological monitoring be conducted in a standardized manner for those undergoing this treatment.
CAR T-Cell Therapy Recipients May Require Specialized COVID-19 Vaccine Strategies
November 3rd 2021CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.
New Drug Approvals Expand cGVHD Treatment Beyond Steroids, But Real-World Data Still Needed
October 30th 2021Ruxolitinib and belumosudil represent FDA-approved treatment options to manage cGVHD, however, real world data will determine best practices for treatment and future research directions within the space.
EC-18 Improves Length and Frequency of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 29th 2021The small molecule oral immunomodulator EC-18 reduced the duration and incidence of severe oral mucositis in patients with head and neck cancer undergoing concurrent chemoradiation.